Why the frontier in AI drug discovery is shifting from generating plausible molecules to experimentally proving which designs survive chemistry, biology and translational constraints.
Primary / high-quality sources: Nature Communications · Evaluating generative models for structure-based drug discovery (Oct. 1, 2026) · International Journal of Molecular Sciences · Translational readiness of AI-generated molecules (2026)
A model can generate chemically formatted structures at enormous scale. That establishes computational capability, not biological efficacy, safety, synthesizability or clinical value.
Validity, uniqueness, novelty and diversity are useful generator metrics, but they do not establish whether a molecule binds the intended target, works in cells or can become a medicine.
When models use a target's three-dimensional structure, they can optimize candidates around a binding site. Yet scoring and docking remain approximations that require experimental confirmation.
A useful drug candidate must balance potency with selectivity, solubility, permeability, metabolic stability, toxicity risk and manufacturability. Improving one property can worsen another.
Synthesis and biological assays reveal which computational predictions survive contact with physical reality. Those measurements become new evidence for model comparison and redesign.
Failed compounds are not wasted if the loop captures them. They can expose model blind spots, improve training data and prevent repeated exploration of unproductive chemical space.
Activity in a biochemical assay is far from a medicine. Cell models, pharmacokinetics, toxicology, animal studies and ultimately human trials progressively test whether an effect is robust and useful.
As molecular generation gets cheaper, high-quality experimental feedback may become the strategic bottleneck. The strongest discovery systems may be those that connect AI design tightly to automated, reproducible wet-lab learning loops.